Moderna Aktie News

Calpers slashed investments in Verizon, Disney, and Peloton stock, and doubled down on Moderna shares in the first quarter.

Pharma stocks and massive potential go hand in hand. With devastating diseases like cancer, diabetes and heart disease still far from finding a cure, drugs that treat these conditions often command exorbitant prices.

Investors and analysts broadly expected the biotech's results to wither in the first quarter, and they were right. Still, it did better than many anticipated.

Here are two biotech stocks to watch after their recent earnings report.

Moderna Inc (NASDAQ: MRNA) reported a narrower-than-expected loss for the first quarter of the year, setting a positive tone as it prepares to launch its second product in the U.S. market later this year. Moderna beats loss estimates, revenue expectations In the first quarter, Moderna recorded a net loss of $1.175 billion, or $3.

Large-cap growth funds have been in the sweet spot for a few years now, thanks to megacap tech holdings.

The company reiterated its full-year 2024 sales guidance of roughly $4 billion, which includes revenue from the expected launch of its RSV vaccine.

Moderna on Thursday reported quarterly revenue that beat Wall Street estimates but came in dramatically lower than the previous year when demand for COVID-19 vaccines was higher.